Amgen Files 2024 10-K: Financials and Operations Detailed
Ticker: AMGN · Form: 10-K · Filed: 2025-02-14T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, financials, biotechnology, debt
TL;DR
Amgen's 2024 10-K is in. Full financials and biz ops for the year are out. Check it.
AI Summary
Amgen Inc. filed its 2024 10-K on February 14, 2025, detailing its fiscal year ending December 31, 2024. The company, a leader in biological products, is headquartered in Thousand Oaks, California. The filing covers its financial performance and business operations for the year, including details on its common stock and specific debt instruments like the A2.00 Senior Notes Due 2026.
Why It Matters
This 10-K filing provides investors and analysts with a comprehensive overview of Amgen's financial health, strategic direction, and potential risks for the fiscal year 2024, influencing investment decisions.
Risk Assessment
Risk Level: medium — As a large biotechnology company, Amgen faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.
Key Numbers
- 2024 — Fiscal Year (The period covered by the 10-K filing.)
- 1231 — Fiscal Year End (Indicates the end date of the reporting period.)
- 001-37702 — SEC File Number (Amgen's SEC filing identification number.)
Key Players & Entities
- AMGEN INC (company) — Filer of the 10-K
- 0000318154 (company) — Central Index Key for Amgen Inc.
- 2024-12-31 (date) — Fiscal year end
- 2025-02-14 (date) — Filing date
- ONE AMGEN CENTER DRIVE (location) — Business and mailing address
- THOUSAND OAKS (location) — City of business and mailing address
- CA (location) — State of business and mailing address
- 91320 (location) — ZIP code of business and mailing address
- A2.00 Senior Notes Due 2026 (dollar_amount) — Specific debt instrument mentioned
FAQ
What is Amgen's primary business as indicated by its SIC code?
Amgen's Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
When did Amgen change its name previously?
Amgen's former company name was changed on March 5, 1987.
What is the filing date of this 10-K report?
This 10-K report was filed on February 14, 2025.
What is the fiscal year end for Amgen?
Amgen's fiscal year ends on December 31st.
What specific debt instrument is mentioned in the filing data?
The filing data mentions 'A2.00 Senior Notes Due 2026' as a specific debt instrument.
From the Filing
0000318154-25-000010.txt : 20250214 0000318154-25-000010.hdr.sgml : 20250214 20250214161841 ACCESSION NUMBER: 0000318154-25-000010 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 156 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250214 DATE AS OF CHANGE: 20250214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 25629161 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-K 1 amgn-20241231.htm 10-K amgn-20241231 0000318154 false 2024 FY http://fasb.org/srt/2024#PartnershipInterestMember http://fasb.org/srt/2024#PartnershipInterestMember http://fasb.org/us-gaap/2024#OtherGeneralExpense http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent iso4217:USD xbrli:shares iso4217:USD xbrli:shares amgn:segment xbrli:pure amgn:notice amgn:case iso4217:EUR iso4217:GBP iso4217:CHF amgn:renewal_options amgn:patent amgn:plaintiff amgn:claim amgn:lawsuit amgn:state amgn:installment 0000318154 2024-01-01 2024-12-31 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000318154 amgn:A2.00SeniorNotesDue2026Member 2024-01-01 2024-12-31 0000318154 2024-06-30 0000318154 2025-02-11 0000318154 2024-10-01 2024-12-31 0000318154 us-gaap:ProductMember 2024-01-01 2024-12-31 0000318154 us-gaap:ProductMember 2023-01-01 2023-12-31 0000318154 us-gaap:ProductMember 2022-01-01 2022-12-31 0000318154 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-12-31 0000318154 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0000318154 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0000318154 2023-01-01 2023-12-31 0000318154 2022-01-01 2022-12-31 0000318154 2024-12-31 0000318154 2023-12-31 0000318154 us-gaap:CommonStockMember 2021-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0000318154 us-gaap:RetainedEarningsMember 2021-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000318154 2021-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000318154 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000318154 us-gaap:CommonStockMember 2022-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000318154 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0000318154